Compare 3M Company (MMM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Twist Bioscience Corp — how do they compare? 3M Company trades at $163.61 (market cap $83.61B), while Twist Bioscience Corp trades at $157.11 (market cap $10.32B). The key difference: 3M Company is far larger — about 8.1× Twist Bioscience Corp's market cap, and 3M Company pays a 1.92% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold 3M Company for 169 Days and Twist Bioscience Corp for 27 Days on average.
| MMM | TWST | |
|---|---|---|
Market Cap | $83.61B | $10.32B |
Volume | 3,188,723 | 5,894,998 |
Sector | Industrials | Health |
52-Week High | $183.79 | $205.00 |
52-Week Low | $141.10 | $25.45 |
Typical Hold Time | 169 Days | 27 Days |
Enterprise Value | $92.83B | $10.24B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMM trades at $162.12, down 0.93% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.40, exceeding expectations, and maintains a robust net income margin of 11.9%. Analyst consensus is mixed with a $191 price target, while recent news highlights operational turnaround progress and litigation management.
The outlook balances solid fundamentals against high debt and weak consumer demand. Upside potential exists from industrial strength and shareholder returns, but risks include cost pressures and macroeconomic headwinds. The stock's current valuation at a P/E of 28.8 requires sustained earnings growth to justify further gains.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
